Patents by Inventor Ryan James LINDER

Ryan James LINDER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250228848
    Abstract: The present disclosure provides the compound of Formula I: or pharmaceutically acceptable salts thereof, methods and intermediates useful in preparing the compound of Formula I, pharmaceutical compositions containing the compound of Formula I, and methods of treating cancer using the compound of Formula I.
    Type: Application
    Filed: April 7, 2023
    Publication date: July 17, 2025
    Inventors: Serge Louis BOULET, Lee Joseph BURNS, Kevin Paul COLE, Xueqian GONG, Deqi GUO, David Michael HYMAN, Michael Edward LAURILA, Ryan James LINDER, Sheng-Bin PENG, James Craig RUBLE, Chong SI, Hannah Leslie VONESH
  • Patent number: 11498915
    Abstract: The present invention relates to compound of the following structure for use as an inhibitor of TrkA, as well as compositions including this compound, and methods of using this compound for the treatment of pain including post-surgical pain, rheumatoid arthritis pain, neuropathic pain and osteoarthritis pain.
    Type: Grant
    Filed: May 24, 2021
    Date of Patent: November 15, 2022
    Assignee: ELI LILLY AND COMPANY
    Inventors: David A. Coates, Ryan James Linder, Laia Malet-Sanz
  • Publication number: 20210371399
    Abstract: The present invention relates to compound of the following structure for use as an inhibitor of TrkA, as well as compositions including this compound, and methods of using this compound for the treatment of pain including post-surgical pain, rheumatoid arthritis pain, neuropathic pain and osteoarthritis pain.
    Type: Application
    Filed: May 24, 2021
    Publication date: December 2, 2021
    Inventors: David A. Coates, Ryan James Linder, Laia Malet-Sanz
  • Patent number: 10968214
    Abstract: The present invention provides compounds of the Formula I below where R1, R2 and m are as described herein, pharmaceutically acceptable salts of the compounds of Formula 1, and methods of using these compounds and salts for treating patients for cancer.
    Type: Grant
    Filed: October 8, 2019
    Date of Patent: April 6, 2021
    Assignee: Eli Lilly and Company
    Inventors: David Anthony Barda, David Andrew Coates, Ryan James Linder, Sheng-Bin Peng, Mohammad Sadegh Zia-Ebrahimi
  • Publication number: 20200115375
    Abstract: The present invention provides compounds of the Formula I below where R1, R2 and m are as described herein, pharmaceutically acceptable salts of the compounds of Formula 1, and methods of using these compounds and salts for treating patients for cancer.
    Type: Application
    Filed: October 8, 2019
    Publication date: April 16, 2020
    Inventors: David Anthony BARDA, David Andrew COATES, Ryan James LINDER, Sheng-Bin PENG, Mohammad Sadegh ZIA-EBRAHIMI